Core Viewpoint - Sentiment around Eli Lilly has deteriorated after a multi-year run, leading to underperformance relative to the market as investors await more clarity [1]. Company Analysis - Eli Lilly is considered a strong buy due to its industry-leading incretin treatments, expanding capacity, and pricing power, which are expected to drive broader adoption and sustained margin growth [3]. - The company is positioned for years of compounding revenue and earnings expansion as a result of these factors [3]. Market Context - The broader sector has also experienced a decline in sentiment, contributing to Eli Lilly's underperformance [1].

After a multi-year run, sentiment around Eli Lilly (NYSE: LLY ) and the broader sector has deteriorated. This has resulted in steep underperformance relative to the market, driven by the market waiting for more clarityI am currently studying economics and accounting at UCSB, and interning at a UBS wealth management office. I am seeking a career in equity research, and I became passionate about equities through managing a stock portfolio of companies that I track closely.Analyst’s Disclosure:I/we have a bene ...